HAVCR2 and myelodysplastic syndrome: With the accumulation of evidence from more large-scale clinical trials, TIM-3 is expected to become a key molecule in the precision treatment and immunotherapy of MDS, and may play an indispensable role in improving the prognosis of MDS patients in the future.